Released : Jun 29, 2017

RNS Number : 5837J

Tiziana Life Sciences PLC

29 June 2017

 

Tiziana Life Sciences plc

("Tiziana" or "the Company")

 

Results of Annual General Meeting

 

At the Annual General Meeting of the Company held at 10.30 a.m. on Thursday 29 June 2017 all the resolutions proposed were duly passed.

 

Details of the proxy voting at the Annual General Meeting will be posted to the Company's website later today.

 

For more information go to http://www.tizianalifesciences.com

 

Contact:

 

Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder	+44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner	+44 (0)20 7213 0880
Beaufort Securities Limited (Broker) Saif Janjua	+44 (0)20 7382 8300
FTI Consulting Simon Conway / Natalie Garland-Collins	+44 (0)20 3727 1000

 

About Tiziana Life Sciences

 

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

RAGSEUFSUFWSEFM